Literature DB >> 8863823

Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe.

A P Kennedy1, K C Mangum, J Linden, J N Wells.   

Abstract

Structure-based design of subtype-selective ligands for the A1 adenosine receptor will require a reliable model of the ligand-binding pocket. It should be possible to develop a reliable model based on the results of affinity labeling experiments that provide atomic coordinates for the ligand in relation to predicted receptor helices. A high affinity, A1-selective xanthine antagonist photoaffinity probe, 125l-3-(4-azidophenethyl)-1-propyl-B-cyclopentylxanthine, was used to covalently modify the A1 receptor. Chemical or enzymatic fragmentation experiments were performed to localize the region or regions of incorporation within the receptor. The fragmentation profiles for radiolabeled A1 receptor obtained with endoproteinase Glu-C, endoproteinase Lys-C, cyanogen bromide, and hydroxylamine were consistent with the interpretation that the covalent linkage was within the first four predicted transmembrane regions. This interpretation was confirmed by the demonstration that the radioactive endoproteinase Glu-C fragment derived from an A1 receptor that contains an amino-terminal FLAG epitope was recognized by an anti-FLAG monoclonal antibody. Sequential digestion with endoproteinase Glu-C/endoproteinase Lys-C limited the possible labeling to the first three predicted transmembrane spans, and endoproteinase Glu-C/trypsin digestion refined this prediction to include only transmembrane spans III and IV. Taken together, our findings suggest that the adenosine antagonist 125l-3-(4-azidophenethyl)-1-propyl-8-cyclopentyl-xanthine covalently modifies transmembrane III of the A1 receptor because this was the only receptor region common to all radiolabeled fragments.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863823

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.

Authors:  Q Jiang; B X Lee; M Glashofer; A M van Rhee; K A Jacobson
Journal:  J Med Chem       Date:  1997-08-01       Impact factor: 7.446

2.  Functionalized congeners of tyrosine-based P2X(7) receptor antagonists: probing multiple sites for linking and dimerization.

Authors:  Wangzhong Chen; R Gnana Ravi; Sylvia B Kertesy; George R Dubyak; Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2002 Sep-Oct       Impact factor: 4.774

3.  Activation induces structural changes in the liganded angiotensin II type 1 receptor.

Authors:  Martin Clément; Jérôme Cabana; Brian J Holleran; Richard Leduc; Gaétan Guillemette; Pierre Lavigne; Emanuel Escher
Journal:  J Biol Chem       Date:  2009-07-27       Impact factor: 5.157

Review 4.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

Review 5.  Molecular probes for the human adenosine receptors.

Authors:  Xue Yang; Laura H Heitman; Adriaan P IJzerman; Daan van der Es
Journal:  Purinergic Signal       Date:  2020-12-12       Impact factor: 3.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.